| scholarly article | Q13442814 |
| P2093 | author name string | Courtney D Fitzhugh | |
| John F Tisdale | |||
| Matthew M Hsieh | |||
| Charles D Bolan | |||
| Carla Saenz | |||
| P2860 | cites work | Hydroxyurea therapy for pediatric patients with hemoglobin SC disease | Q33338213 |
| Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. | Q33362778 | ||
| A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. | Q33998299 | ||
| Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen | Q80237546 | ||
| Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents | Q80829495 | ||
| Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease | Q81362121 | ||
| Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies | Q81471277 | ||
| Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation | Q83118100 | ||
| Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease | Q83365182 | ||
| Reduced Red Cell Glycolysis, 2,3-Diphosphoglycerate and Adenosine Triphosphate Concentration, and Increased Hemoglobin-Oxygen Affinity Caused by Hypophosphatemia | Q93818717 | ||
| Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia | Q34308407 | ||
| Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials | Q34558598 | ||
| Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy | Q34560161 | ||
| A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group | Q34743741 | ||
| Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium | Q35592216 | ||
| Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation | Q35848787 | ||
| Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia | Q35925078 | ||
| Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer | Q36029532 | ||
| Prediction of adverse outcomes in children with sickle cell anemia: a study of the Dallas Newborn Cohort. | Q36384757 | ||
| The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer | Q36468076 | ||
| Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review | Q36883365 | ||
| Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins | Q39588255 | ||
| Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium | Q40785644 | ||
| Effect of cytokines and chemokines on sickle neutrophil adhesion to fibronectin. | Q42476322 | ||
| Comparison of retroviral transduction efficiency in CD34+ cells derived from bone marrow versus G-CSF-mobilized or G-CSF plus stem cell factor-mobilized peripheral blood in nonhuman primates. | Q43770828 | ||
| Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait | Q43863907 | ||
| Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma | Q44707850 | ||
| Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. | Q44851645 | ||
| Prediction of adverse outcomes in children with sickle cell disease | Q44990679 | ||
| Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group | Q46151410 | ||
| Beta-thalassaemia major: bone marrow versus peripheral blood stem cell transplantation. | Q46563710 | ||
| Expression of neutrophil antigens after 10 days of granulocyte-colony-stimulating factor | Q47771056 | ||
| Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography | Q47906551 | ||
| Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue | Q48916913 | ||
| A marrow harvest procedure under local anesthesia. | Q51593674 | ||
| No narcosis for bone marrow harvest in autologous bone marrow transplantation. | Q51837727 | ||
| Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. | Q55034829 | ||
| Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. | Q55034877 | ||
| Mortality in sickle cell disease. Life expectancy and risk factors for early death. | Q55065788 | ||
| Granulocyte colony-stimulating factor-based stem cell mobilization in patients with sickle cell disease | Q57099415 | ||
| Energy Expenditure, Inflammation, and Oxidative Stress in Steady-State Adolescents With Sickle Cell Anemia | Q59173843 | ||
| Inhibition of caspase-dependent spontaneous apoptosis via a cAMP-protein kinase A dependent pathway in neutrophils from sickle cell disease patients | Q61713371 | ||
| Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation | Q69110239 | ||
| Sickle erythrocytes adhere to polymorphonuclear neutrophils and activate the neutrophil respiratory burst | Q71099830 | ||
| Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease | Q71250046 | ||
| Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions | Q72300184 | ||
| A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group | Q72336907 | ||
| Elevated serum and bronchoalveolar lavage fluid levels of interleukin 8 and granulocyte colony-stimulating factor associated with the acute chest syndrome in patients with sickle cell disease | Q73309547 | ||
| Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist | Q73652781 | ||
| Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64 | Q73982003 | ||
| Granulocytosis causing sickle-cell crisis | Q77292395 | ||
| Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy | Q78208970 | ||
| Cytokine concentrations in bone marrow of stable sickle cell anemia patients | Q79959588 | ||
| P433 | issue | 4 | |
| P921 | main subject | sickle-cell disease | Q185034 |
| P304 | page(s) | 464-471 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Cytotherapy | Q5201399 |
| P1476 | title | Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium? | |
| P478 | volume | 11 |
| Q38625485 | A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease |
| Q35153756 | Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. |
| Q42184785 | Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation |
| Q48318556 | Automated red blood cell exchange in preparation for filgrastim mobilization of autologous peripheral blood hematopoietic progenitor cells in a patient with sickle cell anemia. |
| Q38817421 | Bone Marrow as a Hematopoietic Stem Cell Source for Gene Therapy in Sickle Cell Disease: Evidence from Rhesus and SCD Patients |
| Q92376464 | Comparative effects of granulocyte-colony stimulating factor and colistin-alone or in combination on burn wound healing in Acinetobacter baumannii infected mice |
| Q26751061 | Customizing the genome as therapy for the β-hemoglobinopathies |
| Q90440857 | Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders |
| Q33971650 | G-CSF induces membrane expression of a myeloperoxidase glycovariant that operates as an E-selectin ligand on human myeloid cells |
| Q58795507 | Gene Therapy for Hemoglobinopathies |
| Q39220089 | Gene Therapy for β-Hemoglobinopathies |
| Q88959062 | Gene therapy for sickle cell disease: An update |
| Q36596865 | Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease |
| Q52719334 | Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. |
| Q36038875 | Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease: Problems and Solutions |
| Q33880244 | Hematopoietic progenitor cell mobilization is more robust in healthy African American compared to Caucasian donors and is not affected by the presence of sickle cell trait |
| Q55004812 | Hematopoietic stem cell mobilization with plerixafor in sickle cell disease. |
| Q58578990 | How we evaluate red blood cell compatibility and transfusion support for patients with sickle cell disease undergoing hematopoietic progenitor cell transplantation |
| Q90179476 | Life-Threatening Infectious Complications in Sickle Cell Disease: A Concise Narrative Review |
| Q37717887 | Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34+ Hematopoietic Stem and Progenitor Cells |
| Q64061469 | Management of Hodgkin Lymphoma in a Sickle Cell Patient: A Case Report |
| Q39100891 | Minimizing Skin Scarring through Biomaterial Design |
| Q37554951 | Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial |
| Q36725749 | No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice |
| Q36423553 | Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype |
| Q64077228 | PGE2 and Poloxamer Synperonic F108 Enhance Transduction of Human HSPCs with a β-Globin Lentiviral Vector |
| Q88618971 | Peripheral hematopoietic stem cell mobilization utilizing growth factors in donors with sickle cell trait is safe and effective |
| Q50145999 | Plerixafor enables the safe, rapid, efficient mobilization of haematopoietic stem cells in sickle cell disease patients after exchange transfusion |
| Q89700366 | Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor |
| Q37623526 | Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. |
| Q50118913 | Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results |
| Q37417406 | Safety of pegfilgrastim (neulasta) in patients with sickle cell trait/anemia. |
| Q38255698 | Side effects of cytokines approved for therapy |
| Q57025291 | Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients |
| Q37429309 | The assessment of human erythroid output in NOD/SCID mice reconstituted with human hematopoietic stem cells |
| Q38908093 | Treosulfan-Based Conditioning Regimen in Sibling and Alternative Donor Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease |
| Q57112197 | Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma |
| Q90678130 | Viagra Enables Efficient, Single-Day Hematopoietic Stem Cell Mobilization |
| Q46661360 | Volunteer unrelated donor experience after administration of filgrastim and apheresis for the collection of haemopoietic stem cells: the Australian perspective |
| Q33570348 | β-globin gene transfer to human bone marrow for sickle cell disease. |
Search more.